|
|
Salvage
therapy in patients with glioblastoma: is there any benefit?
Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J, Fabel K, Grauer O,
Wismeth C, Klinkhammer-Schalke M, Allgauer M, Schuierer G, Koch H, Schlaier J,
Ulrich W, Brawanski A, Bogdahn U, Steinbrecher A
Klinik und
Poliklinik fur Neurologie der Universitat Regensburg im Bezirksklinikum,
Regensburg, Germany.
Background.
Survival after
first-line therapy is poor for patients with glioblastoma.
The role of second-line treatment for recurrent disease is controversial.
The authors studied the outcome in a subset of patients with glioblastoma who
were selected for an aggressive reintervention strategy at the time of
progression.
Their objectives were to improve patients' overall survival with sustained
quality of life and to make comparisons with overall survival in unselected
patients.
Methods.
Overall, 168 patients were
eligible for retrospective analysis.
Ninety patients received specific therapy for disease recurrence (reintervention
group) by specific criteria.
Results.
In the reintervention group,
promising median overall survival (mOS) results after diagnosis (61.5 weeks) and
progression (33 weeks) were obtained.
The progression-free survival (PFS) rate at 12 months and the overall survival
rate were superior in the reintervention group (71% at 12 months and 32% at 24
months) compared with the total cohort (45% and 20%, respectively) and the
standard group (15% and 5%, respectively).
A matched-pair analysis (n = 46 in each group), with an mOS period of 65.5
versus 28.5 weeks, confirmed these data.
Quality of life was stable or slightly improved during reinterventions in a
subset of patients treated within clinical studies.
Conclusions.
The majority of patients in
the current series were treated with a reintervention strategy, which had an
impact on PFS and mOS.
A second resection, focal radiotherapy (in selected cases), and additional
chemotherapeutic regimens should be considered for patients with recurrent
glioblastoma.
Copyright
2003 American Cancer Society.
PMID: 14669289 [PubMed - in process]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14669289&dopt=Abstract
|
